LPCN
ANALYST COVERAGE9 analysts
BUY
+364.6%upside to target
L $6.00
Med $10.50consensus
H $15.00
Buy
778%
Hold
222%
7 Buy (78%)2 Hold (22%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$13.12M
Revenue TTM
Net Income TTM
Free Cash Flow
Gross Margin-8.2%
Operating Margin-605.9%
Net Margin-571.1%
Return on Equity-66.7%
Return on Assets-45.1%
Debt / Equity
Current Ratio9.99
EPS TTM
PRICE
Prev Close
2.22
Open
2.22
Day Range2.22 – 2.27
2.22
2.27
52W Range1.81 – 12.37
1.81
12.37
4% of range
VOLUME & SIZE
Avg Volume
402.2K
FUNDAMENTALS
P/E Ratio
-1.1x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.81
Market-like
TECHNICAL
RSI (14)
31
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 108 days
Sep 8

LPCN News

About

lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Mahesh Patel
Nachiappan ChidambaramSenior Vice President of Research & Development
Logan MorseVice President of Sales, Marketing & Operations
Krista FogartyPrincipal Accounting Officer & Corporation Controller
Anthony DelConte D.Chief Medical Director
Mahesh V. PatelCo-Founder, President, CEO & Director